SUS 📈 Surgical Science Sweden AB - Overview
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0014428512
SUS: Virtual Reality Simulators, Surgical Training, Medical Education
Surgical Science Sweden AB (publ) is a pioneer in the development and marketing of virtual reality simulators for evidence-based medical training, with a global presence spanning Europe, North and South America, Asia, and international markets. The company's product portfolio includes a range of simulators, such as the Angio Mentor for endovascular training, BRONCH Express, a portable version of the BRONCH Mentor simulator, and ARTHRO Mentor for arthroscopic surgery skills acquisition. These simulators are designed to provide medical professionals with realistic and immersive training experiences, allowing them to hone their skills in a risk-free environment.
The company's simulator offerings also include the BRONCH Mentor for optimizing bronchoscopy training, GI Mentor for GI Endoscopy, HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training, and URO Mentor, a virtual reality simulator for endourology training. Additionally, Surgical Science Sweden AB provides the EndoSim, a realistic scope simulator, and FlexVR, a flexible and portable training platform designed to teach basic and advanced skills for robotic surgery. The LAP Mentor provides a wide array of laparoscopic training cases, while the LapSim training system comprises the LapSim Haptic simulator, LapSim essence, and LapSim 360, which provide laparoscopic training, portable and ready-to-use VR simulation, and high-immersion virtual reality training experiences, respectively.
Surgical Science Sweden AB also offers a range of other simulators, including the MentorLearn, an end-to-end educational platform that streamlines simulation course management, and the LapSim ST, a state-of-the-art training system that prepares students for the operating room. The PELVIC Mentor simulator provides anatomy and pelvic exam training, while the Perc Mentor suite is designed for image-guided interventions. The RobotiX Mentor allows surgeons to practice motor and cognitive skills, and the Simball Box combines digitally collected metrics into a powerful training tool. The company also provides the Spine Mentor, a training simulator for minimal invasive spine surgery, TEE Express, designed to teach Trans-Esophageal Echocardiography procedure, TraumaVR, an ultimate mix of manikin and VR simulation, and Ultrasound Mentor for ultrasound training with multiple medical specialties.
With a history dating back to 1997, Surgical Science Sweden AB is headquartered in Gothenburg, Sweden, and is listed on the stock exchange with the ISIN SE0014428512, classified as a common stock under the GICS Sub Industry: Health Care Technology. The company's commitment to innovation and customer satisfaction has enabled it to establish a strong presence in the global medical training market, with a website available at https://www.surgicalscience.com, providing access to its range of products and services.
Additional Sources for SUS Stock
SUS Stock Overview
Market Cap in USD | 696m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception |
SUS Stock Ratings
Growth 5y | 27.2% |
Fundamental | 33.3% |
Dividend | 18.2% |
Rel. Strength Industry | -579 |
Analysts | - |
Fair Price Momentum | 147.28 SEK |
Fair Price DCF | 37.01 SEK |
SUS Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | -100.00% |
Payout Consistency | 100.0% |
SUS Growth Ratios
Growth Correlation 3m | 81.4% |
Growth Correlation 12m | -62.9% |
Growth Correlation 5y | 37.8% |
CAGR 5y | 14.19% |
CAGR/Mean DD 5y | 0.40 |
Sharpe Ratio 12m | -0.10 |
Alpha | -34.82 |
Beta | 0.91 |
Volatility | 48.37% |
Current Volume | 108k |
Average Volume 20d | 91.3k |
As of December 22, 2024, the stock is trading at SEK 161.50 with a total of 108,004 shares traded.
Over the past week, the price has changed by +4.90%, over one month by +10.24%, over three months by +29.33% and over the past year by -11.17%.
Neither. Based on ValueRay Fundamental Analyses, Surgical Science Sweden AB is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 33.32 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SUS as of December 2024 is 147.28. This means that SUS is currently overvalued and has a potential downside of -8.8%.
Surgical Science Sweden AB has no consensus analysts rating.
According to ValueRays Forecast Model, SUS Surgical Science Sweden AB will be worth about 163.3 in December 2025. The stock is currently trading at 161.50. This means that the stock has a potential upside of +1.13%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 192.2 | 19% |
Analysts Target Price | - | - |
ValueRay Target Price | 163.3 | 1.1% |